Erschienen in:
01.07.2015 | Brief Report
Efficacy and safety of a biosimilar rituximab in biologic naïve patients with active rheumatoid arthritis
verfasst von:
Kuttipurath Kandi Roshique, Vinod Ravindran
Erschienen in:
Clinical Rheumatology
|
Ausgabe 7/2015
Einloggen, um Zugang zu erhalten
Abstract
Biosimilar usage in rheumatology is set to increase over the next few years. This study reports the efficacy and toxicity of a rituximab biosimilar in biologic naïve patients with active rheumatoid arthritis who had inadequately responded to methotrexate. In 21 patients, over a follow-up period of 36 months, it demonstrated prolonged benefit in a majority (10 in remission with disease activity score 28 (DAS28) erythrocyte sedimentation rate (ESR) <2.6 and 9 in low disease activity state with DAS28 ESR between 3.2 and 2.6) and was well tolerated.